Thomas Okarma Appointed CEO of New BioTime Company
BioTime (NYSE: BTX), an Alameda-based company engaged in research and development of innovative new products in the field of regenerative medicine utilizing stem cells and related technology, announced today that it has formed a new wholly owned subsidiary, BioTime Acquisition Corporation, to pursue opportunities and acquire assets and businesses in the fields of stem cells and regenerative medicine. Thomas Okarma, PhD, MD, will serve as the Chief Executive Officer and as a member of the board of directors of BioTime's new subsidiary. Dr. Okarma is the former President and Chief Executive Officer of Geron Corporation and served on that company's board of directors.
Since 2010, BioTime has expanded the scope of its business through strategic acquisitions and has been continually exploring other acquisition opportunities in its fields of interest. BioTime's strategic acquisitions include:
(c) 2013 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.